Amneal Pharmaceuticals Inc. (AMRX)
AMRX Valuation: What 1.69x Sales Means for Investors
Amneal trades at 1.69x sales, below sector benchmarks, as investors weigh raised 2026 profit guidance against Specialty pressure and launch execution.
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results
Amneal's deal to buy Kashiv for up to $1.10B aids biosimilar push. The company posts strong preliminary Q1 results and raises 2026 EPS guidance.
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2026 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2026 Earnings Call Transcript
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.21 per share a year ago.
Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal
Amneal Pharmaceuticals has agreed to acquire biopharma firm Kashiv BioSciences in a cash-and-stock deal worth up to $1.1 billion that will expand the drugmaker's biosimilars business.
Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential
Amneal Pharmaceuticals, Inc. remains a Buy, driven by robust top-line growth, a diversified drug pipeline, and macro demand in key clinical areas. AMRX's FY2025 revenue grew 8% to $3.02B, with positive FY26 guidance and outperformance of Crexont and Brekiya drugs supporting the growth thesis. Despite negative equity and below-investment grade credit, AMRX's 15.2% operating cash flow growth and undervaluation versus peers helps support a bullish outlook.
AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook
Amneal Pharmaceuticals heads into 2026 with diversified growth drivers, rising margins and a faster launch cadence supporting steady revenue expansion.
Is AMRX Stock Undervalued? Sales Multiple, Target, Upside
Amneal Pharmaceuticals trades below peers on sales multiple despite strong gains, with a $14 target hinging on execution, mix shift, and margin strength.
Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing
Amneal Pharmaceuticals taps GLP-1 growth via a Pfizer-linked manufacturing deal, gaining exposure without clinical risks while scaling injectables and peptides.
Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
